Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Calliditas Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA nephropathy

Kinpeygo is the first and only approved treatment for IgAN, a rare, progressive autoimmune disease of the kidney with a high unmet need, with more than 50% of patients potentially progressing to end-stage renal
byBenzinga Newsdesk
February 2, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Kinpeygo is the first and only approved treatment for IgAN, a rare, progressive autoimmune disease of the kidney with a high unmet need, with more than 50% of patients potentially progressing to end-stage renal disease (ESRD)

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

How Google’s Early Bet On AI Has Catapulted The Stock To Record Highs And A 24% Rise For 2024

By Zaheer Anwari
May 24, 10:17 AM
Google has been an early adopter of AI technology, integrating it into core products such as Google Docs, Gmail, and its advertising platforms, which are significant sources of revenue. At the Google I/O developer conference, CEO Sundar Pichai emphasized the critical role of AI by introducing AI-generated answers in Google's search engine.

GOOGL